AstraZeneca’s Anthony Johnson Named CEO of Goldfinch Bio

Goldfinch Bio has appointed Anthony Johnson president and CEO. Johnson joins Cambridge, MA-based Goldfinch from AstraZeneca (NYSE: [[ticker:AZN]]), where he was head of early clinical development for the company’s Innovative Medicine and Early Development Biotech Unit. Last year, Goldfinch raised $55 million in a Series A round of financing to develop new kidney disease treatments based on the genetic components of the condition.

In other moves, Goldfinch named Michael Broxson chief business and operating officer. Broxson held various roles at Takeda Pharmaceutical (OTCMKTS: [[ticker:TKPYY]]), where he was most recently vice president and head of R&D business development.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.